FOLH1 and prostate carcinoma: The first clinical PSMA-based targeted alpha therapy study was published in 2016, where two patients with metastatic castration-resistant prostate cancer with challenging clinical situations received 225Ac-PSMA-617 (100 kBq/Kg) every 2 weeks (74).